MCID: TXC002
MIFTS: 53

Toxic Encephalopathy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 53 15
Neurotoxicity Syndromes 76 53 44
Neurotoxicity 12 54 15
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 44 D020258
NCIt 50 C27961
SNOMED-CT 68 19466003
ICD10 33 G92
UMLS 73 C0235032

Summaries for Toxic Encephalopathy

NINDS : 54 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to alzheimer disease and neuroblastoma. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Oxaliplatin and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and kidney, and related phenotypes are Decreased caspase 3/7 activity and behavior/neurological

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 76 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 31.5 ACHE APP BACE1 BDNF CASP3 GRIN2A
2 neuroblastoma 30.6 APP BACE1 BDNF CASP3 NGF PRNP
3 ischemia 30.5 APP CASP3 HMOX1 TRPV1
4 sensory peripheral neuropathy 30.3 ABCB1 NGF TRPV1
5 status epilepticus 30.2 BDNF CASP3 GRIN2B
6 pheochromocytoma 30.1 CASP3 MAOB NGF TH
7 amyotrophic lateral sclerosis 1 30.0 APP BDNF CASP3 MAOB NGF PRNP
8 hearing loss, noise-induced 30.0 GSTM1 GSTT1 TH
9 peripheral nervous system disease 30.0 ACHE NGF TRPV1
10 autism 29.8 BDNF GRIN2A GRIN2B SLC6A3 TH
11 huntington disease 29.8 BDNF CASP3 GRIN2A GRIN2B PRNP SNCA
12 akinetic mutism 29.8 PRNP SLC6A3
13 tobacco addiction 29.7 GSTM1 GSTT1 SLC6A3
14 fetal alcohol spectrum disorder 29.7 BDNF GRIN2A GRIN2B
15 mood disorder 29.6 BDNF MAOB TH
16 frontotemporal dementia 29.5 ACHE APP PRNP SNCA
17 parkinson disease, late-onset 29.5 ACHE APP BDNF CASP3 HMOX1 MAOB
18 alcohol dependence 29.5 BDNF GRIN2A GRIN2B MAOB SLC6A3
19 bipolar disorder 29.4 APP BDNF GRIN2A GRIN2B SLC6A3 TH
20 dementia 29.3 ACHE APP BACE1 BDNF ITIH4 PRNP
21 schizophrenia 29.3 BACE1 BDNF GRIN2A GRIN2B MAOB SLC6A3
22 central nervous system disease 28.8 APP BACE1 BDNF CASP3 HMOX1 MAOB
23 nervous system disease 28.6 ACHE APP BACE1 BDNF CASP3 GRIN2B
24 phenylketonuria 11.3
25 hepatic encephalopathy 11.3
26 wernicke-korsakoff syndrome 11.3
27 fetal methylmercury syndrome 11.3
28 hypermanganesemia with dystonia 11.1
29 alzheimer disease 2 10.9
30 alzheimer disease mitochondrial 10.9
31 alzheimer disease 4 10.9
32 alzheimer disease 3 10.9
33 alzheimer disease 9 10.9
34 alzheimer disease 18 10.9
35 alzheimer disease 19 10.9
36 kernicterus 10.9
37 hyperbetaalaninemia 10.9
38 encephalopathy 10.8
39 sister chromatid exchange, frequency of 10.3 GSTM1 GSTT1
40 deafness, autosomal recessive 74 10.3 BACE1 CASP3
41 varicocele 10.3 CASP3 GSTM1 GSTT1
42 oral cancer 10.3 CASP3 GSTM1 GSTT1
43 neuropathy 10.3
44 lesion of sciatic nerve 10.3 NGF TRPV1
45 neonatal hypoxic and ischemic brain injury 10.2 BDNF TH
46 paine syndrome 10.2 BDNF NGF TRPV1
47 bile acid synthesis defect, congenital, 1 10.2 GRIN2A GRIN2B
48 substance dependence 10.2 BDNF GSTM1 SLC6A3
49 isolated cleft lip 10.2 GSTM1 GSTT1
50 interstitial cystitis 10.2 BDNF NGF TRPV1

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

GenomeRNAi Phenotypes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 9.02 APP BACE1 CASP3 GRIN2A GRIN2B

MGI Mouse Phenotypes related to Toxic Encephalopathy:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 ABCB1 ABCG2 ACHE APP BACE1 BDNF
2 homeostasis/metabolism MP:0005376 10.36 ABCB1 ABCG2 ACHE APP BACE1 BDNF
3 growth/size/body region MP:0005378 10.32 ABCB1 ACHE APP BACE1 BDNF CASP3
4 cellular MP:0005384 10.31 ABCG2 APP BACE1 BDNF CASP3 HMOX1
5 mortality/aging MP:0010768 10.22 ABCB1 ACHE APP BACE1 BDNF CASP3
6 nervous system MP:0003631 10.22 ABCB1 ABCG2 ACHE APP BACE1 BDNF
7 integument MP:0010771 10.21 ABCG2 APP BACE1 BDNF CASP3 GRIN2A
8 cardiovascular system MP:0005385 10.16 ABCB1 APP CASP3 GRIN2B HMOX1 NGF
9 no phenotypic analysis MP:0003012 10.03 ABCB1 ACHE APP BACE1 BDNF CASP3
10 muscle MP:0005369 9.97 ACHE APP BACE1 CASP3 HMOX1 NGF
11 normal MP:0002873 9.85 ABCG2 APP BACE1 BDNF ITIH4 NGF
12 reproductive system MP:0005389 9.61 ABCB1 ACHE APP BDNF CASP3 HMOX1
13 taste/olfaction MP:0005394 9.02 BDNF CASP3 SLC6A3 SNCA TRPV1

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
4
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
5
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7 Dolutegravir Approved Phase 4 1051375-16-6 54726191
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Cobicistat Approved Phase 4 1004316-88-4
10
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
11
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 113775-47-6 68602 5311068
12
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
14
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 59-43-8, 70-16-6 1130
15
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
16 Cola Phase 4,Phase 3,Phase 2
17 Liver Extracts Phase 4,Not Applicable
18 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antiviral Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Thiamin Phase 4,Phase 2,Phase 3,Not Applicable
28 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
30 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Botulinum Antitoxin Phase 4,Phase 1
34 Botulinum Toxins Phase 4,Phase 1,Not Applicable
35 Antitoxins Phase 4,Phase 1
36 Integrase Inhibitors Phase 4,Not Applicable
37 HIV Integrase Inhibitors Phase 4,Not Applicable
38 Reverse Transcriptase Inhibitors Phase 4,Not Applicable
39 Anti-HIV Agents Phase 4,Not Applicable
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
41 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Not Applicable
42 Anti-Retroviral Agents Phase 4,Not Applicable
43 carnitine Phase 4,Phase 3
44 GABA Agents Phase 4,Phase 3,Not Applicable
45 Anti-Anxiety Agents Phase 4,Phase 3,Not Applicable
46 Adrenergic Agents Phase 4,Phase 3,Phase 2
47 Analgesics Phase 4,Phase 3,Phase 2
48 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Autonomic Agents Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
3 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Completed NCT02051062 Phase 4
4 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
5 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
6 Optimum Thiamine Intervention (OpTIn) Trial Recruiting NCT02788552 Phase 4 Thiamine Hydrochloride
7 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
8 A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) Not yet recruiting NCT03685500 Phase 4 Symtuza® (TAF/FTC/DRV/c);ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
9 L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
10 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
11 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
12 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
13 Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients Unknown status NCT01882621 Phase 3 Monosialoganglioside(GM1);normal saline
14 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
15 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
16 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
17 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 Ganglioside-monosialic acid;placebo
18 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
19 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
20 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Completed NCT00566852 Phase 3 Memantine
21 Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00489411 Phase 3 duloxetine hydrochloride
22 Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Completed NCT00471445 Phase 3 ketamine/amitriptyline NP-H cream
23 Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Completed NCT00363129 Phase 3
24 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00316914 Phase 3 calcium gluconate;magnesium sulfate
25 Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00068445 Phase 3 lamotrigine
26 EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer Completed NCT00046891 Phase 3 Ginkgo Biloba
27 Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy Completed NCT00027963 Phase 3 gabapentin
28 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
29 Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer Completed NCT00112996 Phase 3 alpha-lipoic acid
30 S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo Completed NCT00775645 Phase 3
31 Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer Completed NCT00058071 Phase 3 amifostine trihydrate
32 Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel Completed NCT00039780 Phase 3 BNP7787;Placebo
33 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
34 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
35 Selenium in the Treatment of Arsenic Toxicity and Cancers Completed NCT01442727 Phase 3 sodium selenite;placebo
36 Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism Completed NCT01441557 Phase 2, Phase 3 3,4-diaminopyridine
37 A Study to Compare the Long-term Outcomes After Two Different Anaesthetics Recruiting NCT03089905 Phase 3 Sevoflurane;Remifentanil;Dexmedetomidine
38 Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer Recruiting NCT02251977 Phase 3 GM1;placebo;mFOLFOX6 or XELOX
39 Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients Recruiting NCT03593304 Phase 2, Phase 3 Injection Mecobalamin;Tablet Pyridoxine hydrochlorid;Normal saline;Oral Placebo
40 Alcohol: Thiamine and or Magnesium 1 Recruiting NCT03466528 Phase 2, Phase 3 Magnesium Sulfate;Pabrinex
41 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
42 Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery Active, not recruiting NCT01372774 Phase 3
43 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
44 Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Terminated NCT01279681 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
45 D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain Terminated NCT00301080 Phase 3 D-cycloserine
46 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
47 Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B Withdrawn NCT01940315 Phase 3
48 Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients Unknown status NCT02500810 Phase 2 monosialoganglioside
49 Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin Unknown status NCT00884767 Phase 2 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
50 Effects of Folic Acid Supplementation on Arsenic Lowering Unknown status NCT02235948 Phase 2 folic acid supplementation

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

41
Brain, Testes, Kidney, Eye, Lung, Liver, Spinal Cord

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 139)
# Title Authors Year
1
An aggravated return-to-work case of organic solvent induced chronic toxic encephalopathy. ( 29719722 )
2018
2
Acute toxic encephalopathy induced by occupational exposure to 1,2-dichloropropane. ( 29973469 )
2018
3
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. ( 28748330 )
2018
4
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. ( 28153514 )
2017
5
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. ( 28173825 )
2017
6
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. ( 28807179 )
2017
7
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. ( 29121830 )
2017
8
Routine fruit washing to prevent acute toxic encephalopathy. ( 28807178 )
2017
9
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. ( 27114653 )
2016
10
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. ( 27815462 )
2016
11
Neem oil poisoning - Case report of an adult with toxic encephalopathy. ( 27728581 )
2016
12
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. ( 27673102 )
2016
13
Capecitabine: toxic encephalopathy. ( 26688902 )
2015
14
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. ( 26610794 )
2015
15
A case of life-threatening acute kidney injury with toxic encephalopathy caused by Dioscorea quinqueloba. ( 25510780 )
2015
16
1,2-Dichloroethane-induced toxic encephalopathy: A case series with morphological investigations. ( 25743226 )
2015
17
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. ( 26388394 )
2015
18
Neem oil poisoning as a cause of toxic encephalopathy in an infant. ( 24522945 )
2014
19
Toxic encephalopathy after exposure to azacitidine. ( 25224457 )
2014
20
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. ( 24822136 )
2014
21
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( 24631316 )
2014
22
Toxic encephalopathy due to colchicine--Gloriosa superba poisoning. ( 24591648 )
2014
23
Ethylene glycol toxic encephalopathy. ( 24347968 )
2013
24
MRI brain in monohalomethane toxic encephalopathy: A case report. ( 24347845 )
2013
25
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. ( 23961306 )
2013
26
Neem oil poisoning: Case report of an adult with toxic encephalopathy. ( 24339648 )
2013
27
Toxic encephalopathy. ( 22362126 )
2012
28
Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. ( 22177366 )
2012
29
Toxic encephalopathy. ( 23251840 )
2012
30
Establishment of a poisoned animal model of toxic encephalopathy induced by 1,2-dichloroethane. ( 21329570 )
2011
31
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( 20926454 )
2011
32
Toxic encephalopathy. ( 21590623 )
2011
33
Toxic encephalopathy caused by occupational exposure to 1, 2-Dichloroethane. ( 20163807 )
2010
34
An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? ( 19402572 )
2009
35
Acute toxic encephalopathy due to the ingestion of Rhus extract. ( 19570681 )
2009
36
[Star fruit (Averrhoa carambola) toxic encephalopathy]. ( 18755486 )
2009
37
Toxic encephalopathy after taking dried seeds of Datura stramonium in two elderly subjects. ( 19702945 )
2009
38
Margosa (Kohomba) oil induced toxic encephalopathy following home remedy for intestinal worms. ( 20052860 )
2009
39
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. ( 19596561 )
2009
40
Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. ( 18560254 )
2008
41
Chronic toxic encephalopathy caused by occupational solvent exposure. ( 18409195 )
2008
42
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. ( 19031955 )
2008
43
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. ( 17938643 )
2008
44
Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. ( 17762922 )
2007
45
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. ( 17762322 )
2007
46
Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort. ( 16484635 )
2006
47
Taurine induced toxic encephalopathy? ( 16844286 )
2006
48
Methadone intoxication in a child: toxic encephalopathy? ( 16970857 )
2006
49
Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. ( 16765447 )
2006
50
Toxic encephalopathy and noise-induced hearing loss. ( 17851218 )
2006

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 APP BACE1 BDNF GRIN2A GRIN2B MAOB
2
Show member pathways
13.37 APP BACE1 BDNF CASP3 GRIN2A GRIN2B
3
Show member pathways
12.87 ACHE GRIN2A GRIN2B MAOB SLC6A3 TH
4 12.02 BDNF CASP3 NGF TH
5 11.94 BDNF CASP3 GRIN2B NGF
6 11.76 APP BACE1 GRIN2A GRIN2B NGF PRNP
7
Show member pathways
11.63 ABCG2 GSTM1 GSTT1
8 11.63 CASP3 SLC6A3 SNCA TH
9 11.59 CASP3 GSTM1 GSTT1
10 11.57 ABCG2 BDNF NGF TH
11 11.53 ABCB1 ABCG2 HMOX1
12
Show member pathways
11.5 BDNF GRIN2A GRIN2B MAOB SLC6A3 TH
13
Show member pathways
11.44 APP BDNF CASP3 NGF
14
Show member pathways
11.3 ACHE SLC6A3 TH
15 11.29 APP BACE1 CASP3 PRNP
16 11.07 ABCG2 GSTM1 GSTT1
17 10.96 MAOB SLC6A3 SNCA TH
18 10.77 ABCB1 GSTT1
19 10.74 MAOB TH
20 10.73 BDNF CASP3
21 10.69 ABCB1 ABCG2
22 10.65 ACHE TH

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.91 ACHE APP GRIN2A GRIN2B SNCA TRPV1
2 dendrite GO:0030425 9.88 BACE1 BDNF NGF PRNP TH TRPV1
3 neuron projection GO:0043005 9.8 APP GRIN2A GRIN2B SLC6A3 TH TRPV1
4 membrane raft GO:0045121 9.77 APP BACE1 CASP3 PRNP SLC6A3
5 cell surface GO:0009986 9.76 ABCB1 ACHE APP BACE1 GRIN2A GRIN2B
6 neuronal cell body GO:0043025 9.73 BACE1 CASP3 SLC6A3 SNCA TH TRPV1
7 axon GO:0030424 9.5 APP BACE1 BDNF NGF SLC6A3 SNCA
8 NMDA selective glutamate receptor complex GO:0017146 9.46 GRIN2A GRIN2B
9 synaptic vesicle GO:0008021 9.1 BACE1 BDNF GRIN2A NGF SNCA TH
10 plasma membrane GO:0005886 10.26 ABCB1 ABCG2 ACHE APP BACE1 GRIN2A

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 CASP3 GRIN2A HMOX1 NGF SNCA TRPV1
2 response to lipopolysaccharide GO:0032496 9.9 CASP3 MAOB SNCA TH
3 negative regulation of neuron apoptotic process GO:0043524 9.88 BDNF HMOX1 NGF SNCA
4 locomotory behavior GO:0007626 9.85 APP SLC6A3 TH
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 CASP3 NGF SNCA
6 response to wounding GO:0009611 9.83 ACHE CASP3 GRIN2A
7 memory GO:0007613 9.83 BDNF GRIN2A NGF TH
8 excitatory postsynaptic potential GO:0060079 9.81 GRIN2A GRIN2B SNCA TRPV1
9 learning GO:0007612 9.79 APP GRIN2A TH
10 modulation of chemical synaptic transmission GO:0050804 9.78 BACE1 BDNF GRIN2A NGF
11 positive regulation of neuron apoptotic process GO:0043525 9.77 BACE1 CASP3 PRNP
12 long-term synaptic potentiation GO:0060291 9.76 GRIN2A GRIN2B SNCA
13 positive regulation of neuron death GO:1901216 9.74 GRIN2B PRNP SNCA
14 ionotropic glutamate receptor signaling pathway GO:0035235 9.72 APP GRIN2A GRIN2B
15 response to ethanol GO:0045471 9.72 GRIN2A GRIN2B MAOB SLC6A3 TH
16 neurotrophin TRK receptor signaling pathway GO:0048011 9.71 BDNF CASP3 NGF
17 dopamine metabolic process GO:0042417 9.69 GRIN2A SNCA
18 glutamate receptor signaling pathway GO:0007215 9.69 GRIN2A GRIN2B
19 prepulse inhibition GO:0060134 9.68 BACE1 SLC6A3
20 cellular copper ion homeostasis GO:0006878 9.68 APP PRNP
21 nerve development GO:0021675 9.68 BDNF NGF
22 nerve growth factor signaling pathway GO:0038180 9.67 BDNF NGF
23 negative regulation of activated T cell proliferation GO:0046007 9.67 CASP3 PRNP
24 response to nicotine GO:0035094 9.67 CASP3 HMOX1 SLC6A3 TH
25 negative regulation of long-term synaptic potentiation GO:1900272 9.66 APP PRNP
26 neuron projection maintenance GO:1990535 9.66 APP PRNP
27 neurotransmitter catabolic process GO:0042135 9.65 ACHE MAOB
28 cellular response to alkaloid GO:0071312 9.65 TH TRPV1
29 dopamine catabolic process GO:0042420 9.64 MAOB SLC6A3
30 excitatory chemical synaptic transmission GO:0098976 9.64 GRIN2A GRIN2B
31 mating behavior GO:0007617 9.63 APP TH
32 positive regulation of collateral sprouting GO:0048672 9.63 BDNF NGF
33 neurotransmitter biosynthetic process GO:0042136 9.63 ACHE SLC6A3 TH
34 xenobiotic transport GO:0042908 9.62 ABCB1 ABCG2
35 calcium ion transmembrane import into cytosol GO:0097553 9.61 GRIN2A GRIN2B
36 modulation of age-related behavioral decline GO:0090647 9.61 APP PRNP
37 dopamine biosynthetic process GO:0042416 9.61 SLC6A3 SNCA TH
38 cellular response to manganese ion GO:0071287 9.58 APP BACE1 TH
39 negative regulation of dendritic spine maintenance GO:1902951 9.56 GRIN2B PRNP
40 cellular response to amyloid-beta GO:1904646 9.56 APP BACE1 GRIN2A PRNP
41 cellular response to copper ion GO:0071280 9.46 APP BACE1 PRNP SNCA
42 learning or memory GO:0007611 9.35 APP CASP3 GRIN2A GRIN2B PRNP
43 response to drug GO:0042493 9.23 ABCB1 ABCG2 CASP3 GRIN2A MAOB SLC6A3

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.63 CASP3 PRNP SLC6A3
2 amyloid-beta binding GO:0001540 9.54 ACHE BACE1 PRNP
3 ionotropic glutamate receptor activity GO:0004970 9.43 GRIN2A GRIN2B
4 dopamine binding GO:0035240 9.4 SLC6A3 TH
5 NMDA glutamate receptor activity GO:0004972 9.32 GRIN2A GRIN2B
6 cuprous ion binding GO:1903136 9.26 PRNP SNCA
7 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.16 ABCB1 ABCG2
8 enzyme binding GO:0019899 9.1 APP BACE1 GSTM1 HMOX1 SNCA TH
9 glutamate-gated calcium ion channel activity GO:0022849 8.96 GRIN2A GRIN2B

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....